A new study is suggesting there may be an association with high tumor levels of the protein PD-L1 and head and neck disease recurrence.
Head and Neck Cancer Targets
The US Food and Drug Administration (FDA) in record time has approved nivolumab (Opdivo) for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after a platinum-based therapy.
A 45-year-old man presents with a mass in the right neck. After the biopsy is performed, what is your diagnosis?
Clinicians now have a new treatment option for patients with recurrent or metastatic head and neck squamous cell carcinoma.
In this interview, Theodoros Teknos, MD, discusses the results of his current phase I trial of vorinostat (Zolinza) in advanced head and neck cancer.
Selumetinib has received Orphan Drug Designation status by the US Food and Drug Administration to be used as an adjuvant treatment in patients with stage III or IV differentiated thyroid cancer.
Researchers at Boston University School of Medicine have identified a marker that can detect carcinoma-associated fibroblasts (CAFS) in oral cancer tissues.
In this interview, we speak with Dr. Robert Ferris about the results from the CheckMate-141 study, which investigated the efficacy of nivolumab in head and neck cancer.
Immunotherapy treatment with nivolumab significantly improved survival among patients with recurrent or metastatic head and neck squamous cell carcinoma.
Tobacco smoking worsens the prognosis for patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC), and this is likely due at least in part to differences in the somatic gene mutation signatures of patients with more pronounced smoking histories.